NVAX Novavax Inc

Price (delayed)

$8.94

Market cap

$1.47B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.52

Enterprise value

$1.58B

?
Relative Growth: Rel. Growth: 2
Relative Strength: Rel. Strength: 53
Relative Valuation: Rel. Valuation: 15
Relative Profitability: Rel. Profitability: 18

Novavax, Inc. tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M adjuvant and protein-based nanoparticles. The ...

Highlights
NVAX's quick ratio is down by 6% since the previous quarter but it is up by 2.3% year-on-year
Novavax's net income has plunged by 182% from the previous quarter and by 159% YoY
Novavax's EPS has shrunk by 181% QoQ and by 158% YoY

Key stats

What are the main financial stats of NVAX

NVAX stock price

How has the Novavax stock price performed over time
Intraday
6.18%
1 week
11.06%
1 month
10.71%
1 year
17.17%
YTD
33.04%
QTD
-5.1%

Financial performance

How have Novavax's revenue and profit performed over time
Revenue
$413.8M
Gross profit
$325.26M
Operating income
-$234.12M
Net income
-$247.73M
Gross margin
78.6%
Net margin
-59.9%
Novavax's operating income has plunged by 200% from the previous quarter and by 167% YoY
Novavax's net income has plunged by 182% from the previous quarter and by 159% YoY
NVAX's gross profit has shrunk by 66% YoY and by 36% QoQ
The revenue has plunged by 62% YoY and by 31% from the previous quarter

Price vs fundamentals

How does NVAX's price correlate with its fundamentals

Growth

What is Novavax's growth rate over time

Valuation

What is Novavax stock price valuation
P/E
N/A
P/B
N/A
P/S
3.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.82
Novavax's EPS has shrunk by 181% QoQ and by 158% YoY
Novavax's equity has decreased by 32% QoQ
NVAX's P/S is 70% above its last 4 quarters average of 2.1 and 42% above its 5-year quarterly average of 2.5
The revenue has plunged by 62% YoY and by 31% from the previous quarter

Efficiency

How efficient is Novavax business performance
NVAX's return on assets has dropped by 179% year-on-year
The ROIC has plunged by 131% YoY

Dividends

What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVAX.

Financial health

How did Novavax financials performed over time
Novavax's total assets is 17% lower than its total liabilities
Novavax's total assets has decreased by 29% YoY and by 8% QoQ
The total liabilities has declined by 12% year-on-year and by 3.5% since the previous quarter
NVAX's debt to equity has dropped by 126% year-on-year but it is up by 24% since the previous quarter
Novavax's equity has decreased by 32% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.